Show simple item record

dc.contributor.authorÖcal, Osman
dc.contributor.authorSchinner, Regina
dc.contributor.authorSchütte, Kerstin
dc.contributor.authorde Toni, Enrico N
dc.contributor.authorLoewe, Christian
dc.contributor.authorvan Delden, Otto
dc.contributor.authorVandecaveye, Vincent
dc.contributor.authorGebauer, Bernhard
dc.contributor.authorZech, Christoph J
dc.contributor.authorSengel, Christian
dc.contributor.authorBargellini, Irene
dc.contributor.authorGasbarrini, Antonio
dc.contributor.authorSangro, Bruno
dc.contributor.authorPech, Maciej
dc.contributor.authorMalfertheiner, Peter
dc.contributor.authorRicke, Jens
dc.contributor.authorSeidensticker, Max
dc.contributor.authorSORAMIC study group
dc.date.accessioned2022-03-02T00:30:25Z
dc.date.available2022-03-02T00:30:25Z
dc.date.issued2022-01-04
dc.identifier.issn1740-5025
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/334567
dc.description.abstractBACKGROUND: The aim of this study was to explore the relationship between follow-up imaging characteristics and overall survival (OS) in advanced hepatocellular carcinoma (HCC) patients under sorafenib treatment. METHODS: Associations between OS and objective response (OR) by mRECIST or early tumor shrinkage (ETS; ≥20% reduction in enhancing tumor diameter at the first follow-up imaging) were analyzed in HCC patients treated with sorafenib within a multicenter phase II trial (SORAMIC). 115 patients were included in this substudy. The relationship between survival and OR or ETS were explored. Landmark analyses were performed according to OR at fixed time points. Cox proportional hazards models with OR and ETS as a time-dependent covariate were used to compare survival with factors known to influence OS. RESULTS: The OR rate was 29.5%. Responders had significantly better OS than non-responders (median 30.3 vs. 11.4 months; HR, 0.38 [95% CI, 0.22-0.63], p < 0.001), and longer progression-free survival (PFS; median 10.1 vs. 4.3 months, p = 0.015). Patients with ETS ≥ 20% had longer OS (median 22.1 vs. 11.4 months, p = 0.002) and PFS (median 8.0 vs. 4.3 months, p = 0.034) than patients with ETS < 20%. Besides OR and ETS, male gender, lower bilirubin and ALBI grade were associated with improved OS in univariate analysis. Separate models of multivariable analysis confirmed OR and ETS as independent predictors of OS. CONCLUSION: OR according to mRECIST and ETS in patients receiving sorafenib treatment are independent prognostic factors for OS. These parameters can be used for assessment of treatment benefit and optimal treatment sequencing in patients with advanced HCC.
dc.format.mediumElectronic
dc.publisherSpringer Science and Business Media LLC
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectEarly tumor shrinkage
dc.subjectHepatocellular carcinoma
dc.subjectObjective response
dc.subjectSorafenib
dc.subjectmRECIST
dc.subjectAntineoplastic Agents
dc.subjectCarcinoma, Hepatocellular
dc.subjectHumans
dc.subjectLiver Neoplasms
dc.subjectMale
dc.subjectRetrospective Studies
dc.subjectSorafenib
dc.subjectTreatment Outcome
dc.titleEarly tumor shrinkage and response assessment according to mRECIST predict overall survival in hepatocellular carcinoma patients under sorafenib.
dc.typeArticle
dc.date.updated2022-02-28T14:03:13Z
prism.issueIdentifier1
prism.number1
prism.publicationDate2022
prism.publicationNameCancer Imaging
prism.startingPage1
prism.volume22
dc.identifier.doi10.17863/CAM.81986
dcterms.dateAccepted2021-12-05
rioxxterms.versionofrecord10.1186/s40644-021-00439-x
rioxxterms.versionVoR
dc.identifier.eissn1470-7330
rioxxterms.typeJournal Article/Review
cam.issuedOnline2022-01-04
cam.depositDate2022-02-28
pubs.licence-identifierapollo-deposit-licence-2-1
pubs.licence-display-nameApollo Repository Deposit Licence Agreement


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's licence is described as Attribution 4.0 International